<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Respiratory distress syndrome (RDS) in preterm infants: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Respiratory distress syndrome (RDS) in preterm infants: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Respiratory distress syndrome (RDS) in preterm infants: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard Martin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph A Garcia-Prats, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H23056080">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory distress syndrome (RDS), formerly known as hyaline membrane disease, is the major cause of respiratory distress in preterm infants.
        </p>
        <p>
         The management and complications of RDS in preterm infants will be reviewed here. The pathophysiology, clinical manifestations, and diagnosis of neonatal RDS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5055.html" rel="external">
          "Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         The use of antenatal corticosteroid therapy for prevention of neonatal RDS is also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3202817229">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1857388084">
         <span class="h2">
          Prematurity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Different degrees of prematurity are classifies by gestational age (GA), which is calculated from the first day of the mother's last period, or birth weight (BW), as summarized in the table  (
         <a class="graphic graphic_table graphicRef119362" href="/z/d/graphic/119362.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2787608786">
         <span class="h2">
          Respiratory distress syndrome (RDS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         RDS, formerly known as hyaline membrane disease, is the major cause of respiratory distress in preterm infants. It is diagnosed clinically based upon onset of progressive respiratory insufficiency (eg, work of breathing, oxygen requirement) shortly after birth in a preterm infant, in conjunction with a characteristic chest radiograph  (
         <a class="graphic graphic_diagnosticimage graphicRef52323" href="/z/d/graphic/52323.html" rel="external">
          image 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5055.html" rel="external">
          "Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         RDS is caused by deficiency of surfactant, the phospholipid mixture (predominantly desaturated palmitoyl phosphatidyl choline) that reduces alveolar surface tension. Inadequate surfactant activity results in high surface tension leading to instability of the lungs at end-expiration, low lung volume, and poor compliance. Infants with RDS are unable generate the inspiratory pressure needed to inflate alveolar units, resulting in the development of progressive and diffuse atelectasis. (See
         <a class="medical medical_review" href="/z/d/html/5055.html" rel="external">
          "Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15315699">
         <span class="h1">
          CLINICAL APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following sections detail our approach to the initial respiratory management of very preterm (VPT) infants (gestational age [GA] &lt;32 weeks) who are at risk for RDS. Management and prevention of RDS includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antenatal corticosteroids to reduce the risk of neonatal RDS and bronchopulmonary dysplasia (BPD). This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early use of positive airway pressure to reduce the risk of BPD. (See
         <a class="local">
          'Early positive pressure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other supportive measures to optimize the neonate's metabolic and cardiorespiratory status as the infant transitions from the delivery room to the neonatal intensive care unit (NICU), thereby reducing oxygen consumption and energy expenditures. (See
         <a class="local">
          'Supportive care'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For neonates who require substantial respiratory support (ie, mechanical ventilation or requiring FiO
         <sub>
          2
         </sub>
         [fraction of inspired oxygen] &gt;0.3 to 0.4 on noninvasive support), initial management includes treatment with exogenous surfactant. (See
         <a class="local">
          'Surfactant'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ongoing respiratory support is titrated to achieve adequate oxygenation and ventilation while minimizing further lung injury and complications such as BPD. (See
         <a class="local">
          'Surfactant therapy'
         </a>
         below and
         <a class="local">
          'Subsequent management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         There have been numerous clinical trials evaluating a wide range of interventions for neonates with or at risk for RDS. However, important uncertainties remain and there is variability in the management of RDS from center to center. Our approach described in the sections below is generally consistent with recommendations from the American Academy of Pediatrics (AAP) and other expert panels [
         <a href="#rid1">
          1,2
         </a>
         ]. Links to these and other society guidelines are provided separately. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2881195878">
         <span class="h2">
          Initial management
         </span>
        </p>
        <p class="headingAnchor" id="H2638297566">
         <span class="h3">
          Early positive pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our center, we provide early positive pressure in all VPT infants since these neonates are at high risk for RDS  (
         <a class="graphic graphic_algorithm graphicRef73111" href="/z/d/graphic/73111.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. The choice of respiratory support depends upon the infant's initial respiratory effort [
         <a href="#rid1">
          1,3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For infants with a
         <strong>
          strong respiratory drive
         </strong>
         (ie, sustained regular respirations), noninvasive positive pressure is initially provided to prevent and reduce atelectasis. Nasal continuous positive airway pressure (nCPAP) and nasal intermittent positive pressure ventilation (NIPPV) are both reasonable options for noninvasive support. The choice among these is largely based upon cost and availability. While NIPPV may be more effective than nCPAP in preventing intubation and subsequent respiratory morbidity, it requires a ventilator for administration, which makes it more costly and complex to use. For these reasons, we preferentially use nCPAP for the initial mode of support in our center and reserve NIPPV for infants who fail nCPAP. (See
         <a class="local">
          'Noninvasive positive airway pressure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infants who are
         <strong>
          apneic or have poor respiratory effort
         </strong>
         (gasping) and/or a heart rate &lt;100 beats per minute should be resuscitated with bag mask ventilation (BMV). Infants who do not respond to BMV require intubation and initiation of invasive mechanical ventilation. (See
         <a class="medical medical_review" href="/z/d/html/5015.html" rel="external">
          "Neonatal resuscitation in the delivery room", section on 'Apnea/gasping and heart rate &lt;100 bpm'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3872397670">
         <span class="h3">
          Supplemental oxygen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless of the type of respiratory support, supplemental oxygen is provided to maintain a targeted peripheral oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) between 90 to 95 percent. However, additional interventions (eg, surfactant) are provided to avoid the need for high FiO
         <sub>
          2
         </sub>
         , which can contribute to lung injury. (See
         <a class="medical medical_review" href="/z/d/html/112392.html" rel="external">
          "Neonatal target oxygen levels for preterm infants"
         </a>
         and
         <a class="local">
          'Surfactant therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H896092958">
         <span class="h3">
          Surfactant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surfactant is administered to all intubated patients and to those with persistent hypoxemia after a trial of positive airway pressure (ie, those who require FiO
         <sub>
          2
         </sub>
         &gt;0.3 to 0.4 on noninvasive support to maintain SpO
         <sub>
          2
         </sub>
         &gt;90 percent) [
         <a href="#rid4">
          4,5
         </a>
         ]. Traditionally, surfactant has been instilled through an endotracheal tube after intubation. Increasingly, minimally invasive surfactant therapy (MIST) techniques are used for surfactant administration in select patients to avoid the complications associated with endotracheal intubation. However, the choice of technique varies, as discussed below. (See
         <a class="local">
          'Indications'
         </a>
         below and
         <a class="local">
          'Techniques for administration'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2976162656">
         <span class="h3">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         General supportive care is provided to all preterm infants in the delivery room and as they are transitioned to and cared for in the NICU. The following supportive care measures are focused on optimizing the infant's metabolic and cardiorespiratory status.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thermal neutral environment
         </strong>
         – Infants should be maintained in a thermal neutral environment to minimize heat loss and maintain the core body temperature in a normal range, thereby reducing oxygen consumption and caloric needs. The ambient temperature should be selected to maintain an anterior abdominal skin temperature in the 36.5 to 37°C range. Rectal temperatures should be avoided in infants with RDS because of the greater risk of trauma or perforation associated with their use. As a result, abdominal temperatures are used to set the servo-controlling temperatures in incubators and in radiant warmers. (See
         <a class="medical medical_review" href="/z/d/html/4965.html" rel="external">
          "Overview of short-term complications in preterm infants", section on 'Hypothermia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintaining hemodynamic stability
         </strong>
         – Systemic hypotension occurs commonly in the early stages of RDS. As a result, blood pressure should be frequently monitored noninvasively or continuously via intravascular catheter. Management of hemodynamic instability and low blood pressure is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/126605.html" rel="external">
          "Neonatal shock: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109813.html" rel="external">
          "Assessment and management of low blood pressure in extremely preterm infants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          Caffeine
         </a>
         – In extremely preterm (EPT) infants (GA &lt;28 weeks), initial management includes early administration of caffeine therapy to increase respiratory drive since these patients universally have apnea of prematurity and are at greatest risk for developing BPD. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5048.html" rel="external">
          "Management of apnea of prematurity", section on 'Caffeine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutrition
         </strong>
         – The administration of early nutrition is important in the overall care of preterm infants. Energy needs must cover both metabolic expenditure (eg, resting metabolic rate and thermoregulation) and growth. Nutrition support for preterm infants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">
          "Parenteral nutrition in premature infants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">
          "Approach to enteral nutrition in the premature infant"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid balance
         </strong>
         – Fluids should be adjusted to maintain a neutral to slightly negative water balance, as infants are born in a positive fluid state. (See
         <a class="local">
          'Fluid management'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">
          "Fluid and electrolyte therapy in newborns"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2569830636">
         <span class="h2">
          Subsequent management
         </span>
        </p>
        <p class="headingAnchor" id="H2684536121">
         <span class="h3">
          Ongoing respiratory support
         </span>
         <span class="headingEndMark">
          —
         </span>
         For neonates with strong respiratory drive who have adequate gas exchange on noninvasive support, respiratory support is gradually weaned if the neonate is able to maintain adequate oxygenation (ie, SpO
         <sub>
          2
         </sub>
         between 90 to 95 percent). (See
         <a class="medical medical_review" href="/z/d/html/112392.html" rel="external">
          "Neonatal target oxygen levels for preterm infants"
         </a>
         .)
        </p>
        <p>
         However, despite the use of early supportive measures (eg, nCPAP, surfactant), some preterm neonates have persistent RDS, which may progress. This is generally manifested by increased work of breathing, increasing oxygen requirement, and classical chest radiographic findings  (
         <a class="graphic graphic_diagnosticimage graphicRef52323" href="/z/d/graphic/52323.html" rel="external">
          image 1
         </a>
         ). Patients with persistent or progressive RDS require ongoing respiratory support, which is titrated as needed to achieve adequate gas exchange.
        </p>
        <p>
         For neonates with increased work of breathing and/or high oxygen requirement (ie, requiring FiO
         <sub>
          2
         </sub>
         &gt;0.4), nCPAP support can be increased up to 6 to 8 cm H
         <sub>
          2
         </sub>
         O. Occasionally, higher pressures may be used (up to 10 or 11 cm H
         <sub>
          2
         </sub>
         O). However, in most cases, if the neonate continues to have significant oxygen requirement and/or work of breathing despite optimizing nCPAP, we transition to NIPPV. (See
         <a class="local">
          'Nasal continuous positive airway pressure (nCPAP)'
         </a>
         below and
         <a class="local">
          'Nasal intermittent positive pressure ventilation'
         </a>
         below.)
        </p>
        <p>
         Infants who have ongoing significant distress, ineffective breathing, inadequate gas exchange, and/or significant apnea despite optimizing noninvasive support generally require intubation and invasive mechanical ventilation. Indications for intubation and the approach to mechanical ventilation in VPT infants are summarized in the table  (
         <a class="graphic graphic_table graphicRef131155" href="/z/d/graphic/131155.html" rel="external">
          table 2
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1446657982">
         <span class="h3">
          Post-extubation support
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our center, nCPAP is routinely used for respiratory support in infants with RDS who require intubation and are subsequently extubated. nCPAP reduces the risk of adverse clinical events following extubation (eg, apnea, respiratory acidosis, hypoxemia, and need for reintubation) [
         <a href="#rid6">
          6
         </a>
         ]. NIPPV and high-flow nasal cannula (HFNC) are reasonable alternatives. (See
         <a class="local">
          'Nasal continuous positive airway pressure (nCPAP)'
         </a>
         below and
         <a class="local">
          'Nasal intermittent positive pressure ventilation'
         </a>
         below and
         <a class="local">
          'High-flow nasal cannula'
         </a>
         below.)
        </p>
        <p>
         The efficacy of nCPAP in this setting is supported by randomized controlled trials carried out in the 1990s and early 2000s [
         <a href="#rid6">
          6
         </a>
         ]. In a meta-analysis of eight trials (667 infants), reintubation rates were lower for infants extubated to nCPAP compared with those who were extubated to headbox oxygen (28 versus 47 percent; relative risk [RR] 0.59, 95% CI 0.48-0.72) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Subsequent clinical trials have evaluated nCPAP relative to NIPPV and HFNC [
         <a href="#rid7">
          7-15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CPAP versus NIPPV – In a meta-analysis of 19 trials (2738 infants), infants assigned to NIPPV less frequently required reintubation compared with those assigned to CPAP (27 versus 36 percent; RR 0.75, 95% CI 0.67-0.84) [
         <a href="#rid12">
          12
         </a>
         ]. Other outcomes (including mortality, incidence of BPD, and necrotizing enterocolitis [NEC]) were similar in both groups. Though these data suggest that NIPPV provides modest benefit over nCPAP, we continue to prefer nCPAP because NIPPV requires a ventilator for administration, and it therefore is more costly and complex to use. We limit use of NIPPV in this setting to infants who fail nCPAP. (See
         <a class="local">
          'Nasal intermittent positive pressure ventilation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CPAP versus HFNC – In a meta-analysis of four trials (698 infants), reintubation rates were similar in infants assigned to HFNC or nCPAP (16 versus 17 percent; RR 0.94, 95% CI 0.68-1.31) [
         <a href="#rid6">
          6
         </a>
         ]. Mortality was similar in both groups. In a subsequent trial, more patients assigned to HFNC had treatment failure compared with those assigned to CPAP [
         <a href="#rid14">
          14
         </a>
         ]. However, most neonates who failed HFNC were successfully managed with CPAP such that reintubation rates were similar in both arms (6 versus 9 percent, respectively). These data suggest that HFNC and nCPAP have comparable efficacy in this setting. We generally prefer nCPAP because there is greater experience with this modality in preterm neonates.
        </p>
        <p>
        </p>
        <p>
         The optimal pressure level for nCPAP following extubation is uncertain. Findings from a trial of 93 infants suggest that high versus lower distending pressure (7 to 9 cm versus 4 to 6 cm H
         <sub>
          2
         </sub>
         O) was associated with a lower extubation failure rate and reintubation [
         <a href="#rid16">
          16
         </a>
         ]. However, it remains uncertain whether increasing pressure levels for nCPAP would adversely affect cardiovascular function in preterm infants at risk for or with cardiovascular compromise.
        </p>
        <p class="headingAnchor" id="H2506849470">
         <span class="h3">
          Fluid management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid balance
         </strong>
         – As previously discussed, fluids should be adjusted to maintain a neutral to slightly negative water balance, as infants are born in a positive fluid state. Excessive fluid intake should be avoided as it is associated with patent ductus arteriosus (PDA), necrotizing enterocolitis (NEC), and BPD [
         <a href="#rid17">
          17
         </a>
         ]. Our usual practice is to restrict total fluid intake to 130 to 140 mL/kg per day after the first week of life. However, the fluid status of the patient must be monitored frequently to avoid dehydration or overhydration as fluid needs widely vary in preterm infants due to differences in insensible fluid loss. Caloric intake and growth should be closely monitored. (See
         <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">
          "Fluid and electrolyte therapy in newborns"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The practice of using a modest fluid restriction in preterm neonates with RDS is supported by clinical trials and observational data [
         <a href="#rid17">
          17-19
         </a>
         ]. In a meta-analysis of five trials, fluid restriction decreased the risk of NEC and hemodynamically significant PDA [
         <a href="#rid17">
          17
         </a>
         ]. Rates of BPD were also lower in infants managed with modest fluid restriction, but the finding was not statistically significant (relative risk [RR] 0.85, 95% CI 0.63-1.14). All five trials reported that fluid restriction was associated with a postnatal weight loss, which may increase the risk of dehydration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a retrospective report of preterm infants (birth weight [BW] between 401 and 1000 g) from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network study, infants who either died or developed BPD had a higher fluid intake and a lower weight loss during the first 10 days after birth compared with those who survived without BPD [
         <a href="#rid18">
          18
         </a>
         ]. Similarly, a retrospective single center Canadian study of EPT infants reported that a higher cumulative fluid balance at day 10 of life was associated with a higher risk of BPD and death [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diuretic therapy
         </strong>
         – The available evidence does
         <strong>
          not
         </strong>
         support the routine use of diuretics in preterm infants with RDS [
         <a href="#rid20">
          20
         </a>
         ]. Routine use of diuretics should be avoided because it often results in serum electrolyte abnormalities, especially hyponatremia and hypokalemia, due to urinary loss of sodium and potassium. Loop diuretics are also associated with nephrocalcinosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our practice, use of diuretic therapy is limited to chronically ventilator-dependent infants with moderate to severe pulmonary impairment despite a trial of fluid restriction (130 to 140 mL/kg). In this setting, diuretic therapy is typically given as a trial; it is continued only if improvement is seen (as evidenced by the ability to reduce ventilatory support).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When the decision is made to use diuretic therapy, it typically consists of a trial of enteral
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         (2 mg/kg per day) for three to five days. If the neonate's respiratory status does not improve, diuretic therapy is discontinued. If the patient improves, diuretic therapy is continued, typically with a thiazide diuretic (
         <a class="drug drug_pediatric" data-topicid="13148" href="/z/d/drug information/13148.html" rel="external">
          chlorothiazide
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13357" href="/z/d/drug information/13357.html" rel="external">
          hydrochlorothiazide
         </a>
         ). Serum electrolytes should be measured one to two days after initiating diuretic therapy and after dose increases. During chronic therapy, electrolytes should be monitored at least weekly. Electrolyte supplements should be administered to compensate for increased urinary losses. (See
         <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">
          "Fluid and electrolyte therapy in newborns", section on 'Hypokalemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most of the available clinical trials evaluating routine use of diuretic therapy in preterm neonates were carried out in the 1970s to 1980s and the applicability to modern-day practice is questionable. Nevertheless, the available trial data suggest that routine diuretic therapy does not reduce mortality or rates of BPD [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The selective use of
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         in this setting is supported by observational data. In a cohort of 37,693 preterm infants (GA &lt;29 weeks), approximately half of whom received furosemide, greater exposure to furosemide correlated with decreased risk of BPD [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of diuretics in the management of infants with established BPD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Diuretics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2463449707">
         <span class="h1">
          SPECIFIC INTERVENTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2998135689">
         <span class="h2">
          Noninvasive positive airway pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Noninvasive positive airway pressure, which prevents and reduces atelectasis, should be administered to all very preterm (VPT) infants (ie, gestational age [GA] &lt;32 weeks) since these neonates are at high risk for RDS [
         <a href="#rid1">
          1,22-28
         </a>
         ]. In our center, nasal continuous positive airway pressure (nCPAP) is the preferred modality for noninvasive support.
        </p>
        <p class="headingAnchor" id="H3367926173">
         <span class="h3">
          Nasal continuous positive airway pressure (nCPAP)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In preterm infants at risk for or with established RDS without respiratory failure, nCPAP is our preferred modality for noninvasive positive airway pressure. This approach is consistent with the recommendations from the American Academy of Pediatrics (AAP), American Heart Association (AHA), International Liaison Committee on Resuscitation (ILCOR) guidelines, and the European consensus guidelines [
         <a href="#rid1">
          1-3,29
         </a>
         ]. (See
         <a class="local">
          'Clinical approach'
         </a>
         above and
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p>
         The evidence supporting use of early CPAP in VPT neonates is discussed here. Additional details regarding nCPAP, including a description of different CPAP systems and initial settings, are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Continuous positive airway pressure'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CPAP versus invasive mechanical ventilation
         </strong>
         – Our preference for nCPAP over invasive mechanical ventilation as the initial modality for respiratory support in VPT neonates is supported by clinical trials and meta-analyses that have demonstrated reduced risk of bronchopulmonary dysplasia (BPD) and perhaps lower mortality with CPAP as compared with intubation and invasive mechanical ventilation (with or without surfactant administration) [
         <a href="#rid27">
          27,28,30
         </a>
         ]. In a meta-analysis of three trials (2150 VPT neonates), prophylactic CPAP reduced the incidence of BPD at 36 weeks (34 versus 38 percent; relative risk [RR] 0.89, 95% CI 0.80-0.99) [
         <a href="#rid30">
          30
         </a>
         ]. Mortality was lower in the CPAP group (10 versus 13 percent) but the difference was not statistically significant (RR 0.82, 95% CI 0.66-1.03).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Follow-up studies at 18 to 22 months corrected age showed the group assigned to nCPAP compared with those assigned to intubation and surfactant had less respiratory morbidity and the groups had similar rates of death or neurodevelopmental impairment [
         <a href="#rid31">
          31-33
         </a>
         ]. However, despite the use of CPAP, extremely preterm (gestational age &lt;28 weeks) survivors remain at risk for impaired pulmonary function at eight years of age [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CPAP versus supportive care in neonates with symptomatic RDS
         </strong>
         – In neonates with RDS who have signs of respiratory distress within the first 12 to 24 hours after birth, CPAP reduces mortality and the need for intubation and mechanical ventilation compared with supportive care with only supplemental oxygen. In a meta-analysis of five trials (322 neonates with RDS), CPAP reduced mortality (RR 0.53, 95% CI 0.34-0.83) and reduced the need for invasive MV (typical RR 0.72, 95% CI 0.54 to 0.96) compared with spontaneous breathing with supplemental oxygen as necessary [
         <a href="#rid26">
          26
         </a>
         ]. The incidence of BPD among survivors was similar in both groups (RR 1.04, 95% CI 0.35-3.13). Three of the five trials were performed in the 1970s and the applicability to current practice is uncertain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CPAP versus supportive care in asymptomatic at-risk neonates (prophylactic CPAP)
         </strong>
         – The benefit of early prophylactic CPAP (ie, initiated shortly after delivery regardless of whether the infant has signs of respiratory distress) appears to be more modest. In a meta-analysis of four trials (765 neonates), prophylactic CPAP reduced the need for surfactant compared with initial supportive care (23 versus 30 percent; RR 0.75, 95% CI 0.58-0.96) [
         <a href="#rid30">
          30
         </a>
         ]. The incidence of BPD at 36 weeks was also lower in the CPAP group (10 versus 12 percent), but the difference was not statistically significant (RR 0.76, 95% CI 0.51-1.14). Mortality was similar in both groups (5 percent each).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical trials performed in resource-limited settings have also demonstrated a benefit of early prophylactic CPAP. In a meta-analysis of two trials performed in resource-limited settings, delivery room CPAP reduced the need for intubation compared with supportive care with only supplemental oxygen (RR 0.73, 95% CI 0.56-0.96) [
         <a href="#rid35">
          35
         </a>
         ]. In a separate meta-analysis of two observational studies from resource-limited settings, CPAP was associated with lower mortality compared with delivery room management without CPAP (RR 0.51, 95% CI 0.42-0.62) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CPAP versus NIPPV or HFNC
         </strong>
         – Studies comparing CPAP with nasal intermittent positive pressure ventilation (NIPPV) or high-flow nasal cannula (HFNC) are discussed below. (See
         <a class="local">
          'Nasal intermittent positive pressure ventilation'
         </a>
         below and
         <a class="local">
          'High-flow nasal cannula'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The evidence supporting use of CPAP following extubation is described above. (See
         <a class="local">
          'Post-extubation support'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1212698349">
         <span class="h3">
          Nasal intermittent positive pressure ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         NIPPV provides noninvasive respiratory support with phasic positive pressure ventilation (ie, higher pressure during inspiration, lower pressure during exhalation). It is delivered via nasal prongs or mask using a mechanical ventilator.
        </p>
        <p>
         The available clinical trial evidence suggests that early NIPPV may reduce the need for intubation compared with early CPAP [
         <a href="#rid36">
          36
         </a>
         ]. However, the trials have important limitations, as discussed below. In addition, widespread use of NIPPV routinely in all preterm neonates is generally not feasible since NIPPV requires a ventilator for administration and most centers do not have enough ventilators to support all preterm neonates in this manner. Moreover, most preterm neonates do not require the higher level of ventilatory support that NIPPV provides. For these reasons, many centers, including our own, preferentially use nCPAP for initial support in VPT neonates and reserve use of NIPPV for neonates who fail nCPAP. Routine use of early NIPPV is a reasonable alternative to our approach if resources are available to support such practice.
        </p>
        <p>
         The evidence supporting use of NIPPV in VPT neonates is summarized here. Additional details regarding use of NIPPV in neonates are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Nasal intermittent positive pressure ventilation'
         </a>
         .)
        </p>
        <p>
         In a meta-analysis of 16 trials (1848 neonates), early use of NIPPV reduced the need for intubation compared with early CPAP (15 versus 23 percent; RR 0.67, 95% CI 0.56-0.81) [
         <a href="#rid36">
          36
         </a>
         ].
         <strong>
         </strong>
         The incidence of BPD was modestly lower in the NIPPV group (11 versus 15 percent; RR 0.70, 95% CI 0.52 to 0.92); mortality rates were similar in both groups (7.1 versus 8.6; RR 0.82, 95% CI 0.62-1.10).
        </p>
        <p>
         The meta-analysis was limited to studies in which patients were randomized to NIPPV or CPAP within six hours after birth [
         <a href="#rid36">
          36
         </a>
         ]. As such, it included few patients from the largest trial evaluating this question (the NIPPV Study Group trial) [
         <a href="#rid37">
          37
         </a>
         ]. The NIPPV Study Group trial randomly assigned 1007 extremely low birth weight (&lt;1000 g) neonates to NIPPV or CPAP either for primary support or following extubation. There was no clear benefit of NIPPV in this trial; rates of BPD and mortality were similar in both groups. The inconsistency between this trial and other trials in the meta-analysis may be explained by differences in the study populations and/or the timing of starting NIPPV support.
        </p>
        <p>
         An important limitation of the available trial data is that in most trials, neonates who were assigned to CPAP were not permitted to transition to NIPPV if they developed worsening respiratory compromise. This does not reflect practice in many NICUs where NIPPV is used as a rescue therapy for neonates who fail CPAP. Thus, while the clinical trials suggest that early use of NIPPV may reduce the need for intubation when compared with CPAP alone, it remains uncertain whether this approach is more effective than a strategy of initial CPAP with rescue NIPPV if necessary.
        </p>
        <p>
         Another limitation of these data is that the trials were performed at centers experienced in using NIPPV and the findings may not be generalizable to other centers.
        </p>
        <p>
         In a network meta-analysis of 35 randomized trials evaluating different types of noninvasive respiratory support for neonates with RDS (including NIPPV, CPAP, and HFNC), NIPPV was found to be the most effective modality for reducing the need for invasive mechanical ventilation [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Additional evidence evaluating use of NIPPV following extubation is described above. (See
         <a class="local">
          'Post-extubation support'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2697957718">
         <span class="h3">
          High-flow nasal cannula
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC delivers heated, humidified air at flow rates that are higher than standard low-flow nasal cannula. The flow rate and FiO2 are set by the clinician. Typical initial flow rates for neonates are 4 to 6 L/min up to maximum of 8 L/min. At these flow rates, the amount of positive airway pressure provided by HFNC ranges from 2 to 5 cm H
         <sub>
          2
         </sub>
         O, though it can vary substantially.
        </p>
        <p>
         The evidence supporting use of HFNC in VPT neonates is summarized here. Additional details regarding use of HFNC in neonates are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'High-flow nasal cannula'
         </a>
         .)
        </p>
        <p>
         The available data suggest that HFNC has similar efficacy compared with nCPAP for reducing the need for intubation when used as the primary mode of respiratory support for neonates with RDS [
         <a href="#rid13">
          13,39,40
         </a>
         ]. An advantage of HFNC is that it is associated with a lower risk of nasal trauma. However, the main disadvantage is that the airway pressure delivered to the infant with HFNC is highly variable and difficult to monitor. As a result, we generally prefer nCPAP over HFNC for the initial mode of respiratory support in VPT neonates.
        </p>
        <p>
         In a meta-analysis of nine trials (2042 neonates), intubation rates were similar in infants assigned to HFNC or CPAP (12 percent in both groups; RR 1.04, 95% CI 0.82-1.31) [
         <a href="#rid13">
          13
         </a>
         ]. Both groups also had similar rates of BPD (3.7 versus 3.3 percent) and hospital mortality (1.8 versus 2.3 percent). Nasal trauma occurred less frequently in the HFNC group (6 versus 12 percent; RR 0.49, 95% CI 0.36-0.68).
        </p>
        <p>
         Studies evaluating use of HFNC following extubation are described above. (See
         <a class="local">
          'Post-extubation support'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3696641924">
         <span class="h2">
          Mechanical ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for intubation and the approach to mechanical ventilation in VPT infants are summarized in the table  (
         <a class="graphic graphic_table graphicRef131155" href="/z/d/graphic/131155.html" rel="external">
          table 2
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H705755942">
         <span class="h2">
          Surfactant therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decisions regarding use of surfactant therapy in preterm neonates must address the following [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Criteria for when to give it (see
         <a class="local">
          'Indications'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selection of surfactant product (see
         <a class="local">
          'Specific surfactant agents'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Timing of administration (see
         <a class="local">
          'Timing'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Technique for administration (see
         <a class="local">
          'Techniques for administration'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whether repeat doses are warranted (see
         <a class="local">
          'Repeat doses'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Our approach outlined in the following sections is generally consistent with guidance from the American Academy of Pediatrics (AAP), the European consensus guidelines, the Canadian Paediatric Society, and other expert panels [
         <a href="#rid2">
          2,5,22,41
         </a>
         ]. Links to these and other society guidelines are provided separately. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3537824439">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surfactant is administered to all intubated patients and to those with persistent respiratory insufficiency after a trial of positive airway pressure  (
         <a class="graphic graphic_algorithm graphicRef73111" href="/z/d/graphic/73111.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonates who require intubation for respiratory failure
         </strong>
         – Neonates with RDS who are intubated in the delivery room or early in the NICU course due to significant respiratory compromise should receive surfactant therapy, which is administered via endotracheal tube (ETT). (See
         <a class="local">
          'Administration via ETT'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonates who are managed with noninvasive ventilatory support
         </strong>
         – Different thresholds are used for surfactant therapy depending on the instillation technique (MIST [minimally invasive surfactant therapy] versus INSURE [
         <strong>
          IN
         </strong>
         tubate, instill
         <strong>
          SUR
         </strong>
         factant, then
         <strong>
          E
         </strong>
         xtubate to CPAP]). The choice of technique varies between centers and even between providers within the same center, as discussed below. (See
         <a class="local">
          'Choice of technique'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest the following thresholds for each technique  (
         <a class="graphic graphic_algorithm graphicRef73111" href="/z/d/graphic/73111.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If MIST will be used, our suggested threshold is a requirement of FiO
         <sub>
          2
         </sub>
         ≥ 0.30 to maintain SpO
         <sub>
          2
         </sub>
         &gt;90 percent. (See
         <a class="local">
          'Minimally invasive surfactant therapy (MIST)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the INSURE technique will be used, our suggested threshold is a requirement of FiO
         <sub>
          2
         </sub>
         ≥0.40 to maintain SpO
         <sub>
          2
         </sub>
         &gt;90 percent. (See
         <a class="local">
          'Administration via ETT'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Additional doses may be given depending upon the infant's response, as discussed below. (See
         <a class="local">
          'Repeat doses'
         </a>
         below.)
        </p>
        <p>
         The practice of using these FiO2 thresholds for surfactant therapy is supported by a meta-analysis of five clinical trials in which neonates were randomized to early surfactant with rapid extubation to nCPAP versus later selective surfactant with ongoing mechanical ventilation [
         <a href="#rid42">
          42
         </a>
         ]. Two of the trials used an FiO2 &gt;0.45 as the threshold for surfactant administration, the other three trials used lower FiO2 thresholds. In subgroup analysis, the benefit of early surfactant therapy for reducing the incidence of BPD and pulmonary air leak was greater in trials that used a lower FiO
         <sub>
          2
         </sub>
         threshold.
        </p>
        <p class="headingAnchor" id="H4039139268">
         <span class="h3">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         If surfactant therapy is used, it is most effective when given within the first two hours after birth [
         <a href="#rid5">
          5,43-45
         </a>
         ]. In a meta-analysis of six trials, early surfactant administration (within two hours after birth) was associated with lower risk of BPD and pulmonary air leak compared with delayed administration (given after two hours) [
         <a href="#rid45">
          45
         </a>
         ]. However, the potential benefits of timely administration of surfactant must be balanced with allowing adequate time for an initial trial of nCPAP.
        </p>
        <p>
         Late administration of surfactant (ie, beyond seven days after birth) has been proposed as a potential intervention for ventilator-dependent preterm neonates with the rationale that transient surfactant dysfunction or deficiency may contribute to ongoing respiratory insufficiency in these neonates. However, we suggest
         <strong>
          not
         </strong>
         using this strategy since the available evidence does not support its efficacy [
         <a href="#rid46">
          46-48
         </a>
         ]. In a multicenter trial (Trial of Late Surfactant [TOLSURF]), 511 EPT infants who remained ventilator-dependent at 7 to 14 days of age were randomized to late surfactant treatment or routine care without late surfactant. Both groups had similar rates of survival without BPD at 36 weeks PMA (31 versus 32 percent; RR 0.98; 95% CI 0.75-1.28) and at 40 weeks PMA (59 versus 54 percent, RR 1.08; 95% CI 0.92-1.27) [
         <a href="#rid46">
          46
         </a>
         ]. Of note, all infants in this trial received
         <a class="drug drug_pediatric" data-topicid="106992" href="/z/d/drug information/106992.html" rel="external">
          inhaled nitric oxide
         </a>
         (iNO), which is not a standard therapy in preterm infants with RDS, as discussed below. (See
         <a class="local">
          'Inhaled nitric oxide'
         </a>
         below.)
        </p>
        <p>
         A follow-up report of the TOLSURF trial found that pulmonary morbidity at one year corrected age was similar in both groups [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2112854623">
         <span class="h3">
          Techniques for administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard technique for surfactant administration has been endotracheal intubation and administration via ETT. Other less invasive techniques (ie, MIST) have been developed to reduce the complications associated with endotracheal intubation. Use of MIST has been expanding at many centers, but there remains considerable practice variation.
        </p>
        <p class="headingAnchor" id="H1694965946">
         <span class="h4">
          Choice of technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our center, we use the following approach to selecting a technique for surfactant administration:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For neonates who are likely to require ongoing mechanical ventilation (eg, extremely preterm neonates, neonates with significant apnea, neonates requiring moderate to high ventilatory support), surfactant is administered via ETT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For more mature preterm neonates who meet criteria for surfactant therapy but are not expected to require ongoing mechanical ventilation, we generally prefer MIST over the INSURE technique (
         <strong>
          IN
         </strong>
         tubate, instill
         <strong>
          SU
         </strong>
         rfactant, then
         <strong>
          E
         </strong>
         xtubate).
        </p>
        <p>
        </p>
        <p>
         However, the techniques used for surfactant administration vary between centers, and even between clinicians within a single center. Each center needs to determine how best to optimize delivery of surfactant based on the experience of the clinical staff and the availability of different delivery methods [
         <a href="#rid5">
          5
         </a>
         ]. In addition, prior to routine adaption of a specific technique, each center needs to ensure that health care personnel are adequately trained in the method.
        </p>
        <p class="headingAnchor" id="H2776349860">
         <span class="h4">
          Administration via ETT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endotracheal intubation has been the standard technique of surfactant administration. After intubation, surfactant is instilled through an end-hole catheter cut to a standard length of 8 cm or through a secondary lumen of a dual-lumen endotracheal tube. During administration, oxygen saturation needs to be monitored, as oxygen desaturation may occur (see
         <a class="local">
          'Adverse effects'
         </a>
         below). Following instillation, positive pressure ventilation is provided.
        </p>
        <p>
         For neonates requiring ongoing mechanical ventilation, the infant is placed on the ventilator following surfactant administration and ventilator settings are subsequently adjusted as needed to maintain adequate gas exchange. (See
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p>
         For neonates who do not have an ongoing requirement for mechanical ventilation (ie, more mature preterm infants with strong respiratory drive), some centers may use the INSURE technique. INSURE consists of endotracheal intubation and instillation of surfactant, followed by a brief period of bag ventilation, and then rapid extubation to nCPAP. As previously discussed, we generally prefer MIST over INSURE for neonates who do not require ongoing mechanical ventilation since MIST completely avoids bag ventilation and the available data suggest it may reduce the risk of BPD. (See
         <a class="local">
          'Choice of technique'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4142434052">
         <span class="h4">
          Minimally invasive surfactant therapy (MIST)
         </span>
         <span class="headingEndMark">
          —
         </span>
         MIST (also called less invasive surfactant administration [LISA]) most commonly refers to surfactant administration via a thin intratracheal catheter. Other minimally invasive techniques include aerosolized/nebulized surfactant preparations, pharyngeal instillation, and laryngeal mask airway-aided delivery [
         <a href="#rid50">
          50-60
         </a>
         ]. There is a wide variation in techniques used for MIST and in patient selection [
         <a href="#rid61">
          61-63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thin intratracheal catheter administration
         </strong>
         – The best studied MIST technique is the use of thin intratracheal catheter. In this method, the neonate maintains spontaneous breathing on nCPAP while surfactant is gradually instilled in small aliquots through a thin catheter. This technique has been adopted by many centers, including ours, as it appears to be effective in delivering surfactant endotracheally without the complications associated with standard intubation. In our center, we use this technique selectively in more mature preterm neonates who meet criteria for surfactant therapy but are not expected to require ongoing mechanical ventilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of MIST via thin intratracheal catheter is supported by clinical trials and meta-analyses [
         <a href="#rid64">
          64-67
         </a>
         ]. A 2021 systematic review and meta-analysis identified 16 trials comparing MIST via thin catheter versus surfactant administration via ETT [
         <a href="#rid66">
          66
         </a>
         ]. Most trials used an INSURE technique as the control; two trials used endotracheal intubation with delayed extubation. MIST reduced the need for intubation during the first 72 hours (23 versus 36; RR 0.63, 0.54-0.74), reduced the incidence of BPD at 36 weeks PMA (10 versus 18 percent; RR 0.57, 95% CI 0.45-0.74), and reduced in-hospital mortality (8 versus 13 percent; RR 0.63, 95% CI 0.47-0.84). Similar findings were reported in a separate meta-analysis that included many of the same clinical trials [
         <a href="#rid67">
          67
         </a>
         ]. However, the trials in these meta-analyses had important methodologic limitations (including small sample size, lack of blinding, selective reporting, and incomplete follow-up) which may have led to an overestimate the true effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a subsequent large multicenter trial (OPTIMIST-A) published after the meta-analysis, MIST reduced the incidence of BPD in survivors at 36 weeks PMA compared with a sham procedure without surfactant administration (37 versus 45 percent; RR 0.83, 95% CI 0.7-0.98); though the trial did not detect a difference in hospital mortality (11.6 versus 8.2 percent; RR 1.41; 95% CI 0.73-2.7) [
         <a href="#rid68">
          68
         </a>
         ]. A follow-up study of the OPTIMIST-A trial reported two-year outcomes for 400 of the 438 surviving infants (91 percent) from the original trial [
         <a href="#rid69">
          69
         </a>
         ]. Fewer patients in the MIST group were hospitalized for respiratory illness in the first two years (25 versus 38 percent; RR 0.66 (95% CI 0.54-0.81) and parental/caregiver report of wheezing or breathing difficulty was less common in the MIST group (41 versus 54 percent; RR 0.76, 05% CI 0.63-0.90). Among patients who underwent complete neurodevelopmental assessment (n = 381), rates of neurodevelopmental impairment were similar in both groups (26 versus 28 percent; RR 0.94, 95% CI 0.71-1.25). There were five late deaths after discharge from the birth hospitalization (one on the MIST group, and four in the control group).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Taken together, the findings from the meta-analysis and OPTIMIST-A trial suggest that MIST improves short- and long-term pulmonary outcomes (ie, reduced need for intubation, reduced incidence of BPD, fewer respiratory illnesses during the first two years); however, these benefits may not translate into meaningful improvements in long-term neurodevelopmental outcomes. Nevertheless, we continue to use MIST via thin intratracheal catheter at our center in appropriate candidates (more mature preterm neonates who are not expected to require ongoing mechanical ventilation) given the demonstrated pulmonary benefits.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other noninvasive techniques
         </strong>
         – Other noninvasive methods that are being used to deliver surfactant including the use of laryngeal mask airway and aerosolized surfactant delivered through a nebulizer [
         <a href="#rid60">
          60,70,71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a 2021 meta-analysis of nine trials (999 infants), nebulized surfactant compared with standard intubation reduced intubation rates at 72 hours after birth (40 versus 53 percent, RR 0.73, 95% CI 0.63-0.84) [
         <a href="#rid72">
          72
         </a>
         ]. However, this finding is limited by methodologic limitations of the trials, including lack of blinding, early termination, protocol deviations, and incomplete follow-up.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H715941383">
         <span class="h3">
          Repeat doses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional doses of surfactant are administered if the patient has a persistent oxygen requirement with an FiO
         <sub>
          2
         </sub>
         ≥0.30:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For intubated neonates who require ongoing mechanical ventilation with an FiO
         <sub>
          2
         </sub>
         ≥0.30 to maintain SpO
         <sub>
          2
         </sub>
         &gt;90 percent, up to three or four additional doses of surfactant can be given over 48 hours, no more frequently than every 12 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For neonates who received the first dose via MIST and continue to require an FiO
         <sub>
          2
         </sub>
         ≥0.30 to maintain SpO
         <sub>
          2
         </sub>
         &gt;90 percent, a second dose of surfactant is administered via MIST 12 hours after the first. If the neonate successfully weans to FiO2 &lt;0.3, no additional doses of surfactant are necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who received the initial dose via the INSURE technique who are successfully extubated to CPAP and weaned to FiO
         <sub>
          2
         </sub>
         &lt;0.30, no additional doses of surfactant are necessary.
        </p>
        <p>
        </p>
        <p>
         In the available clinical trials, repeated surfactant administration compared with a single dose decreased mortality and morbidity in infants &lt;30 weeks gestation with RDS [
         <a href="#rid43">
          43,73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3901774293">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surfactant administration may be complicated by transient airway obstruction and associated desaturation and/or bradycardia [
         <a href="#rid22">
          22,74
         </a>
         ]. Rare complications include pulmonary hemorrhage and pneumothorax [
         <a href="#rid75">
          75
         </a>
         ]. If the ETT or tracheal catheter is not in the proper position, surfactant may inadvertently be instilled into only one lung (typically the right lung). This can result in a substantial difference between right-sided and left-sided lung compliance, which may contribute to risk of pulmonary air leak. (See
         <a class="medical medical_review" href="/z/d/html/4995.html" rel="external">
          "Pulmonary air leak in the newborn"
         </a>
         .)
        </p>
        <p>
         Other adverse events can occur as a consequence of the intubation procedure itself. (See
         <a class="local">
          'Complications of intubation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4234403250">
         <span class="h3">
          General efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of exogenous surfactant replacement therapy is supported by numerous clinical trials and meta-analyses which have demonstrated that surfactant reduces mortality and morbidity associated with RDS in preterm infants especially for extremely preterm infants (&lt;28 weeks GA), who are at the greatest risk for RDS [
         <a href="#rid43">
          43,68,76-80
         </a>
         ]. In clinical trials, surfactant therapy compared with placebo reduced the incidence and severity of RDS, mortality, and other associated complications including BPD, pulmonary interstitial emphysema, pneumothorax, and other pulmonary air leak complications [
         <a href="#rid77">
          77,79-81
         </a>
         ]. In a meta-analysis of 10 trials (1469 neonates), treatment with natural surfactants reduced all-cause mortality compared with placebo or other control (19 versus 28 percent; RR 0.68, 95% CI 0.57-0.82) [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2878575179">
         <span class="h3">
          Specific surfactant agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surfactant agents include natural and synthetic surfactants. Both types of surfactants are effective, but in clinical trials, natural surfactants have been shown to be superior to synthetic preparations that do not contain protein B and C analogues [
         <a href="#rid22">
          22,83,84
         </a>
         ]. In particular, the use of natural preparations was associated with lower ventilator requirements, decreased mortality, and lower rate of RDS complications in preterm infants.
        </p>
        <p>
         Natural surfactants derived from either bovine or porcine lungs are commercially available in the United States and Canada and the choice of surfactant is based on availability and institutional preference  (
         <a class="graphic graphic_table graphicRef59110" href="/z/d/graphic/59110.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12717" href="/z/d/drug information/12717.html" rel="external">
          Poractant alfa
         </a>
         – Porcine lung minced extract
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13109" href="/z/d/drug information/13109.html" rel="external">
          Calfactant
         </a>
         – Bovine lung lavage extract
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13040" href="/z/d/drug information/13040.html" rel="external">
          Beractant
         </a>
         – Bovine lung minced extract
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="132787" href="/z/d/drug information/132787.html" rel="external">
          Bovine lipid extract surfactant
         </a>
         (BLES) – Bovine lung lavage extract
        </p>
        <p>
        </p>
        <p>
         Natural surfactants are obtained by either animal lung lavage or by mincing animal lung tissue, and subsequently purified by lipid extraction that removes hydrophilic components, including hydrophilic surfactant proteins A and D. The purified lipid preparation retains surfactant proteins B and C, neutral lipids, and surface-active phospholipids (PL) such as dipalmitoylphosphatidylcholine (DPPC). DPPC is the primary surface-active component that lowers alveolar surface tension.
        </p>
        <p>
         The following data compare the effectiveness amongst the three natural preparations. In clinical practice, the choice of surfactant is based on availability and institutional preference.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a large observational study of 51,282 infants, similar outcomes were reported for three surfactant preparations (
         <a class="drug drug_pediatric" data-topicid="13040" href="/z/d/drug information/13040.html" rel="external">
          beractant
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13109" href="/z/d/drug information/13109.html" rel="external">
          calfactant
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12717" href="/z/d/drug information/12717.html" rel="external">
          poractant alfa
         </a>
         ) for mortality and the risk of air leaks or BPD [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis that included 16 trials, direct comparisons were made between various surfactant preparations [
         <a href="#rid86">
          86
         </a>
         ]. Similar outcomes of mortality and BPD were observed between bovine lung lavage and bovine minced lung surfactant extracts either in prophylactic trials (RR 1.02, 95% CI 0.89-1.17) or treatment trials (RR 0.95, 95% CI 0.86-1.06) [
         <a href="#rid86">
          86
         </a>
         ]. Mortality prior to hospital discharge was higher in the bovine minced versus porcine minced lung surfactant extract groups (RR 1.44, 95% CI 1.04-2.00) and a lower risk of death or oxygen requirement at 36 weeks' postmenstrual age was also noted (RR 1.57, 95% CI 1.29-1.92). However, the benefit derived from the porcine preparation was only observed when given in a higher initial dose, and it was uncertain whether the observed benefit was due to the difference in the dose or source of extraction. Results were similar between bovine lung lavage compared with porcine minced lung surfactant (RR 1.4, 95% CI 0.51-3.87). There were no studies comparing bovine lung lavage to porcine lung lavage surfactant or porcine minced lung to porcine lung lavage surfactant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, another meta-analysis reported porcine and bovine minced surfactant extracts had similar rates of mortality (odds ratio [OR] 1.35 95% CI 0.98-1.86), BPD (OR 1.25, 95% CI 0.96-1.62), pneumothorax (OR 1.21, 95% CI 0.72-2.05), and air leak syndrome (OR 2.28, 95% CI 0.82-6.39) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although, the US Food and Drug Administration (FDA) approved the first synthetic peptide-containing surfactant (lucinactant) [
         <a href="#rid88">
          88,89
         </a>
         ], it is no longer commercially available as the manufacturer has voluntarily discontinued production.
        </p>
        <p class="headingAnchor" id="H506800948">
         <span class="h2">
          Unproven and ineffective therapies
         </span>
        </p>
        <p class="headingAnchor" id="H2170668946">
         <span class="h3">
          Surfactant in combination with budesonide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on the use of combination surfactant plus
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         are limited. This therapy cannot be recommended until there are more definitive data establishing its safety and efficacy. The data supporting this intervention are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5023.html" rel="external">
          "Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants", section on 'Intratracheal glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3923657448">
         <span class="h3">
          Inhaled nitric oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         The available clinical trial data suggest that the use of
         <a class="drug drug_pediatric" data-topicid="106992" href="/z/d/drug information/106992.html" rel="external">
          inhaled nitric oxide
         </a>
         (iNO) either as rescue or routine therapy is
         <strong>
          not
         </strong>
         beneficial in preterm infants with RDS for reducing mortality or BPD. As a result, we concur with AAP guidance and other guidelines recommending that iNO
         <strong>
          not
         </strong>
         be used to treat preterm infants with RDS except in rare cases of pulmonary hypertension or hypoplasia [
         <a href="#rid2">
          2,90
         </a>
         ].
        </p>
        <p>
         The use of iNO in preterm neonates with RDS has been investigated in randomized trials and meta-analyses [
         <a href="#rid91">
          91-102
         </a>
         ]. The available trials had considerable differences in study design (eg, dose, duration, early versus late administration of iNO, and severity of illness). A 2017 systematic review identified 17 trials evaluating iNO in preterm neonates and categorized them into three subgroups: trials examining routine use of iNO in preterm neonates (4 trials); trials examining early iNO use in preterm neonates with severe lung disease (10 trials); and trials examining later use of iNO in preterm neonates at high risk of BPD (3 trials) [
         <a href="#rid101">
          101
         </a>
         ]. Meta-analyses of these trials did not detect a reduction in mortality in any subgroup (for routine use of iNO: RR 0.90, 95% CI 0.74-1.10; for early selective use: RR 1.02, 95% CI 0.89-1.18; for late selective use: RR 1.18, 95% CI 0.81-1.71). Similarly, the meta-analysis did not detect a reduction in rates of BPD at 36 weeks PMA in any subgroup (for routine use of iNO: RR 0.95, 95% CI 0.85-1.05; for early selective use: RR 0.89, 95% CI 0.76-1.04; for late selective use: RR 0.91, 95% CI 0.83-1.01).
        </p>
        <p>
         Observational studies have reported similar findings with little to no difference in mortality between patients who received iNO compared with those who did not [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         It is uncertain whether there is a subset of patients who may benefit from iNO. A patient-level meta-analysis of three trials involving preterm infants (GA &lt;34 weeks) receiving respiratory support reported a significant subgroup effect according to race [
         <a href="#rid102">
          102
         </a>
         ]. In this analysis, iNO reduced rates of BPD among Black infants (42 versus 57 percent; RR 0.88, 95% CI 0.8-0.98), but the effect in White infants was nonsignificant (61 versus 63 percent; RR 0.98, 95% CI 0.85-1.12). However, given the large number of subgroup analyses performed and the fact that the subgroup finding was not consistent across outcomes (ie, there was no apparent subgroup effect on mortality), it is likely that the difference according to race represents a spurious finding.
        </p>
        <p>
         While iNO does not appear to be effective in the routine management of preterm neonates with RDS, it is a well-established treatment for term or late preterm infants with persistent pulmonary hypertension, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/135094.html" rel="external">
          "Persistent pulmonary hypertension of the newborn (PPHN): Management and outcome", section on 'Inhaled nitric oxide (iNO)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23056249">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine use of antenatal corticosteroids and surfactant therapy has lowered the mortality and morbidity associated with RDS [
         <a href="#rid43">
          43,76-78
         </a>
         ]. Nevertheless, complications and deaths still persist. Complications may occur as a consequence of the lung disease itself or from therapeutic interventions such as positive pressure ventilation, intubation, and mechanical ventilation.
        </p>
        <p class="headingAnchor" id="H2658789965">
         <span class="h2">
          Complications of noninvasive ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Noninvasive ventilation (including nasal continuous positive airway pressure [nCPAP], nasal intermittent positive pressure ventilation [NIPPV], high-flow nasal cannula [HFNC]) is generally well tolerated in preterm neonates and complications are uncommon. Potential complications include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal injury – Skin breakdown can occur from the pressure of the nasal interface. The risk is greater with nCPAP and NIPPV compared with HFNC [
         <a href="#rid40">
          40
         </a>
         ]. Longer duration of positive pressure support also increases the risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumothorax – All forms of positive pressure ventilation have the potential to cause pulmonary air leak. However, the risk associated with noninvasive support is generally less than with invasive mechanical ventilation. (See
         <a class="medical medical_review" href="/z/d/html/4995.html" rel="external">
          "Pulmonary air leak in the newborn", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric distention – Theoretically, noninvasive positive pressure can cause the neonate to swallow more air which might lead to gastric distention and other gastrointestinal complications (eg, vomiting, feeding intolerance). However, in practice, noninvasive respiratory support using typical settings for RDS (eg, nCPAP of 5 to 7 cm H
         <sub>
          2
         </sub>
         O) has little impact on abdominal distention or feeding tolerance in most neonates [
         <a href="#rid104">
          104
         </a>
         ]. Abdominal distention can occasionally occur with NIPPV, especially when high pressures are used.
        </p>
        <p>
        </p>
        <p>
         Complications of noninvasive ventilation in pediatric patients are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/100358.html" rel="external">
          "Noninvasive ventilation for acute and impending respiratory failure in children", section on 'Complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23056256">
         <span class="h2">
          Complications of intubation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse events are common during neonatal endotracheal intubation. This can range from minor transient desaturation and/or bradycardia to full cardiopulmonary arrest [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
         Preterm neonates are at substantially higher risk of experiencing displacement of the endotracheal tube (ETT) compared with larger term neonates and older infants. This can result in loss of the airway (self extubation) or mainstem intubation. ETT displacement into the mainstem bronchus (typically right-sided) is a particularly common complication, resulting in hyperinflation of the ventilated lung and atelectasis of the contralateral lung. The hyperinflation may contribute to air leak. (See
         <a class="medical medical_review" href="/z/d/html/4995.html" rel="external">
          "Pulmonary air leak in the newborn"
         </a>
         and
         <a class="local">
          'Pulmonary air leak'
         </a>
         below.)
        </p>
        <p>
         Other complications from intubation include laryngeal injury and subglottic stenosis [
         <a href="#rid106">
          106
         </a>
         ]. Esophageal and pharyngeal perforations rarely occur and may be confined to the mediastinum or extend into the pleural cavity. (See
         <a class="medical medical_review" href="/z/d/html/6379.html" rel="external">
          "Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia", section on 'Glottic and subglottic damage'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23056267">
         <span class="h2">
          Pulmonary air leak
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary air leak is a complication of RDS that most commonly affects low birth weight infants (birth weight &lt;1500 g). Air leaks are due to the rupture of an overdistended alveolus and may occur spontaneously or arise from positive pressure ventilation.
        </p>
        <p>
         The clinical features, diagnosis, and management of each of these pulmonary air leak disorders are discussed elsewhere in the program. (See
         <a class="medical medical_review" href="/z/d/html/4995.html" rel="external">
          "Pulmonary air leak in the newborn"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23056274">
         <span class="h2">
          Bronchopulmonary dysplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchopulmonary dysplasia (BPD) is the main chronic complication of RDS. Despite improvements in the management of RDS, the incidence of BPD is still substantial. The etiology of BPD is multifactorial. Inflammation, caused by volutrauma, barotrauma, oxygen toxicity, or infection, plays an important role in its development. This is compounded by the premature lung's structural and functional immaturity, including poorly developed airway support structures, surfactant deficiency, decreased compliance, underdeveloped antioxidant mechanisms, and inadequate fluid clearance.
        </p>
        <p>
         The pathogenesis, clinical features, and management of bronchopulmonary dysplasia are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3242577527">
         <span class="h2">
          Other complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other short- and long-term complications of preterm birth are discussed in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/4965.html" rel="external">
          "Overview of short-term complications in preterm infants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5033.html" rel="external">
          "Overview of the long-term complications of preterm birth"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H540952139">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115866.html" rel="external">
          "Society guideline links: Bronchopulmonary dysplasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3526650551">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83622.html" rel="external">
          "Patient education: When a baby is born premature (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23056281">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Respiratory distress syndrome (RDS) is the major cause of respiratory distress in very preterm (VPT; gestational age [GA] &lt;32 weeks) neonates. It is caused by surfactant deficiency and is manifested by progressive respiratory insufficiency (eg, work of breathing, oxygen requirement) shortly after birth in a preterm infant, in conjunction with a characteristic chest radiograph  (
         <a class="graphic graphic_diagnosticimage graphicRef52323" href="/z/d/graphic/52323.html" rel="external">
          image 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5055.html" rel="external">
          "Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial respiratory support for VPT neonates
         </strong>
         – The choice of initial respiratory support in VPT neonates depends upon the neonate's respiratory effort  (
         <a class="graphic graphic_algorithm graphicRef73111" href="/z/d/graphic/73111.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Strong respiratory drive
         </strong>
         – For neonates with a strong respiratory drive, we recommend noninvasive positive airway pressure rather than supportive care alone initially and rather than proceeding directly to invasive mechanical ventilation (MV) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ); we suggest nasal continuous positive airway pressure (nCPAP) for this purpose rather than other modalities (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Nasal intermittent positive pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC) are reasonable alternatives. (See
         <a class="local">
          'Early positive pressure'
         </a>
         above and
         <a class="local">
          'Noninvasive positive airway pressure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Apneic or poor respiratory effort
         </strong>
         – Infants who are apneic or have poor respiratory effort with a heart rate &lt;100 beats per minute require resuscitation with bag mask ventilation (BMV) as discussed separately. Infants who do not respond to BMV require intubation and initiation of invasive MV. (See
         <a class="medical medical_review" href="/z/d/html/5015.html" rel="external">
          "Neonatal resuscitation in the delivery room", section on 'Apnea/gasping and heart rate &lt;100 bpm'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surfactant
         </strong>
         – For neonates requiring mechanical ventilation and those with persistent hypoxemia despite a trial of positive airway pressure, we recommend surfactant rather than supportive interventions without surfactant (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We define persistent hypoxemia as requiring FiO
         <sub>
          2
         </sub>
         &gt;0.3 to 0.4 on noninvasive support to maintain oxygen saturation &gt;90 percent. Additional surfactant doses may be required if the neonate continues to have a significant oxygen requirement after the first dose. (See
         <a class="local">
          'Surfactant therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Natural surfactant preparations are commercially available  (
         <a class="graphic graphic_table graphicRef59110" href="/z/d/graphic/59110.html" rel="external">
          table 3
         </a>
         ) and the choice of surfactant is based on availability and institutional preference. (See
         <a class="local">
          'Specific surfactant agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Supportive care is provided to optimize the neonate's metabolic and cardiorespiratory status. This includes the following measures, which are discussed separately (see
         <a class="local">
          'Supportive care'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maintenance of thermal neutral environment (see
         <a class="medical medical_review" href="/z/d/html/4965.html" rel="external">
          "Overview of short-term complications in preterm infants", section on 'Hypothermia'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Optimal fluid balance with avoidance of fluid overload (see
         <a class="local">
          'Fluid management'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">
          "Fluid and electrolyte therapy in newborns"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemodynamic support, if needed (see
         <a class="medical medical_review" href="/z/d/html/5039.html" rel="external">
          "Neonatal shock: Etiology, clinical manifestations, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109813.html" rel="external">
          "Assessment and management of low blood pressure in extremely preterm infants"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          Caffeine
         </a>
         therapy for neonates with clinically significant apnea and in all extremely preterm infants (GA &lt;28 weeks) (see
         <a class="medical medical_review" href="/z/d/html/5048.html" rel="external">
          "Management of apnea of prematurity", section on 'Caffeine'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early nutrition (see
         <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">
          "Parenteral nutrition in premature infants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">
          "Approach to enteral nutrition in the premature infant"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ongoing respiratory support
         </strong>
         – After providing initial supportive measures and surfactant (if indicated), ongoing respiratory support is titrated as needed to achieve adequate gas exchange. (See
         <a class="local">
          'Subsequent management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For neonates with strong respiratory drive who have adequate gas exchange on noninvasive support, respiratory support is gradually weaned if the neonate is able to maintain adequate oxygen saturation (ie, 90 to 95 percent). (See
         <a class="local">
          'Ongoing respiratory support'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/112392.html" rel="external">
          "Neonatal target oxygen levels for preterm infants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For neonates with increased work of breathing and/or high oxygen requirement (ie, requiring FiO
         <sub>
          2
         </sub>
         &gt;0.4), nCPAP support can be increased up to 6 to 8 cm H
         <sub>
          2
         </sub>
         O. If this is inadequate, the neonate can be transitioned to NIPPV. (See
         <a class="local">
          'Nasal continuous positive airway pressure (nCPAP)'
         </a>
         above and
         <a class="local">
          'Nasal intermittent positive pressure ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neonates who have significant distress, ineffective breathing, inadequate gas exchange, and/or significant apnea despite optimizing noninvasive support generally require intubation and invasive mechanical ventilation. Indications for intubation and the approach to mechanical ventilation in VPT infants are summarized in the table  (
         <a class="graphic graphic_table graphicRef131155" href="/z/d/graphic/131155.html" rel="external">
          table 2
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For neonates with RDS who require intubation and are subsequently extubated, we recommend routine use of noninvasive positive pressure following extubation rather than supportive care alone (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ); we suggest nCPAP for this purpose rather than other modalities (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). NIPPV or HFNC are reasonable alternatives. (See
         <a class="local">
          'Post-extubation support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Complications may occur as a consequence of the lung disease itself or from therapeutic interventions such as positive pressure ventilation, intubation, and mechanical ventilation. Bronchopulmonary dysplasia (BPD) is the main chronic complication of RDS. (See
         <a class="local">
          'Complications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H111940727">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Stephen E Welty, MD, and Firas Saker, MD, FAAP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Committee on Fetus and Newborn, American Academy of Pediatrics. Respiratory support in preterm infants at birth. Pediatrics 2014; 133:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweet DG, Carnielli VP, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology 2023; 120:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aziz K, Lee HC, Escobedo MB, et al. 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs H, Lindner W, Leiprecht A, et al. Predictors of early nasal CPAP failure and effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of &lt;29 weeks gestational age. Arch Dis Child Fetal Neonatal Ed 2011; 96:F343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng EH, Shah V. Guidelines for surfactant replacement therapy in neonates. Paediatr Child Health 2021; 26:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson KN, Roberts CT, Manley BJ, Davis PG. Interventions to Improve Rates of Successful Extubation in Preterm Infants: A Systematic Review and Meta-analysis. JAMA Pediatr 2017; 171:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis PG, Lemyre B, de Paoli AG. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev 2001; :CD003212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Paoli AG, Davis PG, Lemyre B. Nasal continuous positive airway pressure versus nasal intermittent positive pressure ventilation for preterm neonates: a systematic review and meta-analysis. Acta Paediatr 2003; 92:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalaf MN, Brodsky N, Hurley J, Bhandari V. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation. Pediatrics 2001; 108:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhandari V. Nasal intermittent positive pressure ventilation in the newborn: review of literature and evidence-based guidelines. J Perinatol 2010; 30:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramaswamy VV, Bandyopadhyay T, Nanda D, et al. Efficacy of noninvasive respiratory support modes as postextubation respiratory support in preterm neonates: A systematic review and network meta-analysis. Pediatr Pulmonol 2020; 55:2924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemyre B, Deguise MO, Benson P, et al. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev 2023; 7:CD003212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodgson KA, Wilkinson D, De Paoli AG, Manley BJ. Nasal high flow therapy for primary respiratory support in preterm infants. Cochrane Database Syst Rev 2023; 5:CD006405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchiyama A, Okazaki K, Kondo M, et al. Randomized Controlled Trial of High-Flow Nasal Cannula in Preterm Infants After Extubation. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanbar LJ, Shalish W, Latremouille S, et al. Cardiorespiratory behavior of preterm infants receiving continuous positive airway pressure and high flow nasal cannula post extubation: randomized crossover study. Pediatr Res 2020; 87:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzzella B, Claure N, D'Ugard C, Bancalari E. A randomized controlled trial of two nasal continuous positive airway pressure levels after extubation in preterm infants. J Pediatr 2014; 164:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2014; :CD000503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh W, Poindexter BB, Perritt R, et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005; 147:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soullane S, Patel S, Claveau M, et al. Fluid status in the first 10 days of life and death/bronchopulmonary dysplasia among preterm infants. Pediatr Res 2021; 90:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart A, Brion LP, Soll R. Diuretics for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2011; :CD001454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg RG, Gayam S, Savage D, et al. Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. J Pediatr 2019; 208:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polin RA, Carlo WA, Committee on Fetus and Newborn, American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics 2014; 133:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999; 103:E24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Marter LJ, Allred EN, Pagano M, et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000; 105:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aly H, Milner JD, Patel K, El-Mohandes AA. Does the experience with the use of nasal continuous positive airway pressure improve over time in extremely low birth weight infants? Pediatrics 2004; 114:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho JJ, Subramaniam P, Davis PG. Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants. Cochrane Database Syst Rev 2020; 10:CD002271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer HS, Bührer C. Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. Pediatrics 2013; 132:e1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmölzer GM, Kumar M, Pichler G, et al. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ 2013; 347:f5980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlman JM, Wyllie J, Kattwinkel J, et al. Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2015; 132:S204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramaniam P, Ho JJ, Davis PG. Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants. Cochrane Database Syst Rev 2021; 10:CD001243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010; 362:1970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaucher YE, Peralta-Carcelen M, Finer NN, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 2012; 367:2495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens TP, Finer NN, Carlo WA, et al. Respiratory outcomes of the surfactant positive pressure and oximetry randomized trial (SUPPORT). J Pediatr 2014; 165:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle LW, Carse E, Adams AM, et al. Ventilation in Extremely Preterm Infants and Respiratory Function at 8 Years. N Engl J Med 2017; 377:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramaswamy VV, Abiramalatha T, Bandyopadhyay T, et al. Delivery room CPAP in improving outcomes of preterm neonates in low-and middle-income countries: A systematic review and network meta-analysis. Resuscitation 2022; 170:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemyre B, Deguise MO, Benson P, et al. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev 2023; 7:CD005384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirpalani H, Millar D, Lemyre B, et al. A trial comparing noninvasive ventilation strategies in preterm infants. N Engl J Med 2013; 369:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramaswamy VV, More K, Roehr CC, et al. Efficacy of noninvasive respiratory support modes for primary respiratory support in preterm neonates with respiratory distress syndrome: Systematic review and network meta-analysis. Pediatr Pulmonol 2020; 55:2940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts CT, Owen LS, Manley BJ, et al. Nasal High-Flow Therapy for Primary Respiratory Support in Preterm Infants. N Engl J Med 2016; 375:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruet S, Butin M, Dutheil F. Systematic review of high-flow nasal cannula versus continuous positive airway pressure for primary support in preterm infants. Arch Dis Child Fetal Neonatal Ed 2022; 107:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee S, Fernandez R, Fox GF, et al. Surfactant replacement therapy for respiratory distress syndrome in preterm infants: United Kingdom national consensus. Pediatr Res 2019; 86:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007; :CD003063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suresh GK, Soll RF. Overview of surfactant replacement trials. J Perinatol 2005; 25 Suppl 2:S40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000; :CD001456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2012; 11:CD001456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballard RA, Keller RL, Black DM, et al. Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. J Pediatr 2016; 168:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hascoët JM, Picaud JC, Ligi I, et al. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial. JAMA Pediatr 2016; 170:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughon M, Bose C, Moya F, et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics 2009; 123:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keller RL, Eichenwald EC, Hibbs AM, et al. The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. J Pediatr 2017; 183:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dargaville PA, Aiyappan A, Cornelius A, et al. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed 2011; 96:F243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Latif ME, Osborn DA. Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev 2011; :CD008309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Göpel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011; 378:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanmaz HG, Erdeve O, Canpolat FE, et al. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics 2013; 131:e502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           More K, Sakhuja P, Shah PS. Minimally invasive surfactant administration in preterm infants: a meta-narrative review. JAMA Pediatr 2014; 168:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinheiro JM, Santana-Rivas Q, Pezzano C. Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery. J Perinatol 2016; 36:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts KD, Brown R, Lampland AL, et al. Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial. J Pediatr 2018; 193:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minocchieri S, Berry CA, Pillow JJ, CureNeb Study Team. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2019; 104:F313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herting E, Härtel C, Göpel W. Less invasive surfactant administration (LISA): chances and limitations. Arch Dis Child Fetal Neonatal Ed 2019; 104:F655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jena SR, Bains HS, Pandita A, et al. Surfactant therapy in premature babies: SurE or InSurE. Pediatr Pulmonol 2019; 54:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings JJ, Gerday E, Minton S, et al. Aerosolized Calfactant for Newborns With Respiratory Distress: A Randomized Trial. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klotz D, Porcaro U, Fleck T, Fuchs H. European perspective on less invasive surfactant administration-a survey. Eur J Pediatr 2017; 176:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Kort E, Kusters S, Niemarkt H, et al. Quality assessment and response to less invasive surfactant administration (LISA) without sedation. Pediatr Res 2020; 87:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Luca D, Shankar-Aguilera S, Centorrino R, et al. Less invasive surfactant administration: a word of caution. Lancet Child Adolesc Health 2020; 4:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldana-Aguirre JC, Pinto M, Featherstone RM, Kumar M. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2017; 102:F17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigo V, Lefebvre C, Broux I. Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis. Eur J Pediatr 2016; 175:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Latif ME, Davis PG, Wheeler KI, et al. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev 2021; 5:CD011672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu X, Feng Z, Kong J, et al. Efficacy and safety of surfactant administration via thin catheter in preterm infants with neonatal respiratory distress syndrome: A systematic review and meta-analysis. Pediatr Pulmonol 2021; 56:3013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dargaville PA, Kamlin COF, Orsini F, et al. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA 2021; 326:2478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dargaville PA, Kamlin COF, Orsini F, et al. Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial. JAMA 2023; 330:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts CT, Manley BJ, O'Shea JE, et al. Supraglottic airway devices for administration of surfactant to newborn infants with respiratory distress syndrome: a narrative review. Arch Dis Child Fetal Neonatal Ed 2021; 106:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smee NJ, Boyd D, Conetta H, O'Shea J. Laryngeal mask airway surfactant administration: case series of 60 infants. Arch Dis Child Fetal Neonatal Ed 2021; 106:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaertner VD, Thomann J, Bassler D, Rüegger CM. Surfactant Nebulization to Prevent Intubation in Preterm Infants: A Systematic Review and Meta-analysis. Pediatrics 2021; 148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corbet A, Gerdes J, Long W, et al. Double-blind, randomized trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700 to 1100 grams: effects on mortality rate. American Exosurf Neonatal Study Groups I and IIa. J Pediatr 1995; 126:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarawneh A, Kaczmarek J, Bottino MN, Sant'anna GM. Severe airway obstruction during surfactant administration using a standardized protocol: a prospective, observational study. J Perinatol 2012; 32:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Recommendations for neonatal surfactant therapy. Paediatr Child Health 2005; 10:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980; 1:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 1991; 88:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kendig JW, Notter RH, Cox C, et al. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics 1988; 82:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hintz SR, Poole WK, Wright LL, et al. Changes in mortality and morbidities among infants born at less than 25 weeks during the post-surfactant era. Arch Dis Child Fetal Neonatal Ed 2005; 90:F128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoekstra RE, Jackson JC, Myers TF, et al. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics 1991; 88:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2010; :CD001079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009; :CD007836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update. Neonatology 2010; 97:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardell S, Pfister RH, Soll R. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2015; :CD000144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trembath A, Hornik CP, Clark R, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr 2013; 163:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh N, Halliday HL, Stevens TP, et al. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2015; :CD010249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez Luna M, Bacher P, Unnebrink K, et al. Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials. J Perinatol 2020; 40:1121.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Approval of Lucinactant for neonatal respiratory distress syndrome. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294984.htm (Accessed on March 26, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar P, Committee on Fetus and Newborn, American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. Pediatrics 2014; 133:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349:2099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercier JC, Hummler H, Durrmeyer X, et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet 2010; 376:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrianakos-Hoobler AI, Marks JD, Msall ME, et al. Safety and efficacy of inhaled nitric oxide treatment for premature infants with respiratory distress syndrome: follow-up evaluation at early school age. Acta Paediatr 2011; 100:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasan SU, Potenziano J, Konduri GG, et al. Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr 2017; 171:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinsella JP, Cutter GR, Steinhorn RH, et al. Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns. J Pediatr 2014; 165:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donohue PK, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127:e414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 2011; 128:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2017; 1:CD000509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askie LM, Davies LC, Schreiber MD, et al. Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis. J Pediatr 2018; 193:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey WA, Weaver AL, Mara KC, Clark RH. Inhaled Nitric Oxide in Extremely Premature Neonates With Respiratory Distress Syndrome. Pediatrics 2018; 141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cresi F, Maggiora E, Lista G, et al. Effect of Nasal Continuous Positive Airway Pressure vs Heated Humidified High-Flow Nasal Cannula on Feeding Intolerance in Preterm Infants With Respiratory Distress Syndrome: The ENTARES Randomized Clinical Trial. JAMA Netw Open 2023; 6:e2323052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatch LD, Grubb PH, Lea AS, et al. Endotracheal Intubation in Neonates: A Prospective Study of Adverse Safety Events in 162 Infants. J Pediatr 2016; 168:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratner I, Whitfield J. Acquired subglottic stenosis in the very-low-birth-weight infant. Am J Dis Child 1983; 137:40.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4997 Version 100.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24379228" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Respiratory support in preterm infants at birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36863329" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33087555" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21278432" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Predictors of early nasal CPAP failure and effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of&lt;29 weeks gestational age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33552321" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Guidelines for surfactant replacement therapy in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27918754" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Interventions to Improve Rates of Successful Extubation in Preterm Infants: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687052" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12650303" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Nasal continuous positive airway pressure versus nasal intermittent positive pressure ventilation for preterm neonates: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11433048" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19847188" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nasal intermittent positive pressure ventilation in the newborn: review of literature and evidence-based guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32757365" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Efficacy of noninvasive respiratory support modes as postextubation respiratory support in preterm neonates: A systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37497794" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37144837" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Nasal high flow therapy for primary respiratory support in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33214331" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Randomized Controlled Trial of High-Flow Nasal Cannula in Preterm Infants After Extubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31277077" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cardiorespiratory behavior of preterm infants receiving continuous positive airway pressure and high flow nasal cannula post extubation: randomized crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24094879" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A randomized controlled trial of two nasal continuous positive airway pressure levels after extubation in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25473815" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16356432" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33824447" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fluid status in the first 10 days of life and death/bronchopulmonary dysplasia among preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22161366" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Diuretics for respiratory distress syndrome in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30579586" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24379227" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Surfactant replacement therapy for preterm and term neonates with respiratory distress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9925870" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10835057" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342841" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Does the experience with the use of nasal continuous positive airway pressure improve over time in extremely low birth weight infants?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33058208" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24144716" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24136633" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26472855" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34661278" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20472939" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Early CPAP versus surfactant in extremely preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23268664" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24725582" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Respiratory outcomes of the surfactant positive pressure and oximetry randomized trial (SUPPORT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28745986" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ventilation in Extremely Preterm Infants and Respiratory Function at 8 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34757058" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Delivery room CPAP in improving outcomes of preterm neonates in low-and middle-income countries: A systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37466143" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23944299" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A trial comparing noninvasive ventilation strategies in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32762014" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Efficacy of noninvasive respiratory support modes for primary respiratory support in preterm neonates with respiratory distress syndrome: Systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27653564" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Nasal High-Flow Therapy for Primary Respiratory Support in Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34016651" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Systematic review of high-flow nasal cannula versus continuous positive airway pressure for primary support in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30780152" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Surfactant replacement therapy for respiratory distress syndrome in preterm infants: United Kingdom national consensus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17943779" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15861172" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Overview of surfactant replacement trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796266" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23152207" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26500107" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26928567" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19117865" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28100402" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20971722" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Preliminary evaluation of a new technique of minimally invasive surfactant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21735428" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21963186" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23359581" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25089718" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Minimally invasive surfactant administration in preterm infants: a meta-narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26633145" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29174079" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30049729" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31296694" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Less invasive surfactant administration (LISA): chances and limitations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31424177" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Surfactant therapy in premature babies: SurE or InSurE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33060258" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Aerosolized Calfactant for Newborns With Respiratory Distress: A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27942865" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : European perspective on less invasive surfactant administration-a survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31450233" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Quality assessment and response to less invasive surfactant administration (LISA) without sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32014122" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Less invasive surfactant administration: a word of caution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27852668" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27678511" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33970483" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34215018" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Efficacy and safety of surfactant administration via thin catheter in preterm infants with neonatal respiratory distress syndrome: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34902013" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37695601" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32989046" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Supraglottic airway devices for administration of surfactant to newborn infants with respiratory distress syndrome: a narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33246968" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Laryngeal mask airway surfactant administration: case series of 60 infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34711678" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Surfactant Nebulization to Prevent Intubation in Preterm Infants: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7776110" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Double-blind, randomized trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700 to 1100 grams: effects on mortality rate. American Exosurf Neonatal Study Groups I and IIa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21738121" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Severe airway obstruction during surfactant administration using a standardized protocol: a prospective, observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19668609" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Recommendations for neonatal surfactant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6101413" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Artificial surfactant therapy in hyaline-membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2057268" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3054783" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15724036" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Changes in mortality and morbidities among infants born at less than 25 weeks during the post-surfactant era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2057245" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20091513" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19370695" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Animal derived surfactant extract for treatment of respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20551710" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26009996" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23769501" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Comparative effectiveness of surfactant preparations in premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26690260" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32051542" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32051542" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15805381" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24379225" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Use of inhaled nitric oxide in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645637" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Inhaled nitric oxide in premature infants with the respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16000352" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Inhaled nitric oxide for premature infants with severe respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16870914" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Early inhaled nitric oxide therapy in premature newborns with respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16870913" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20655106" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21054515" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Safety and efficacy of inhaled nitric oxide treatment for premature infants with respiratory distress syndrome: follow-up evaluation at early school age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28973344" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25063725" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21220391" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Inhaled nitric oxide in preterm infants: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21930540" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28045472" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Inhaled nitric oxide for respiratory failure in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29241680" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29439205" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Inhaled Nitric Oxide in Extremely Premature Neonates With Respiratory Distress Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37436750" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Effect of Nasal Continuous Positive Airway Pressure vs Heated Humidified High-Flow Nasal Cannula on Feeding Intolerance in Preterm Infants With Respiratory Distress Syndrome: The ENTARES Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26541424" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Endotracheal Intubation in Neonates: A Prospective Study of Adverse Safety Events in 162 Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6847958" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Acquired subglottic stenosis in the very-low-birth-weight infant.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
